LC–MS/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation

(2021) Mohamed W. Attwa et al.   MOLECULES

Classification of drugs for evaluating drug interaction in drug development and clinical management

(2021) Kazuya Maeda et al.   Drug Metabolism and Pharmacokinetics

Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies

(2020) Eric D. Eisenmann et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment

(2018) Kyle Crassini et al.   BRITISH JOURNAL OF HAEMATOLOGY

Binimetinib for the treatment of NRAS-mutant melanoma

(2017) Paola Queirolo et al.   Expert Review of Anticancer Therapy

MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701

(2017) Chia-Hung Chen et al.   Molecular Oncology

Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination

(2017) Pinaki Sengupta et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

(2014) U. Urner-Bloch et al.   ANNALS OF ONCOLOGY

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

(2013) N. Tan et al.   MOLECULAR CANCER THERAPEUTICS

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

Perspectives on Bioanalytical Mass Spectrometry and Automation in Drug Discovery

(2008) John Janiszewski et al.   CURRENT DRUG METABOLISM